Compare · GILD vs LXEO
GILD vs LXEO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $159.05B, about 481.1x LXEO ($330.6M).
- Over the past year, GILD is up 11.4% and LXEO is down 5.0% - GILD leads by 16.4 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 3 for LXEO).
- GILD has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Gilead Sciences Inc.
- Lexeo Therapeutics Inc.
- Price
- $125.67-1.95%
- $4.16-1.65%
- Market cap
- $159.05B
- $330.6M
- 1M return
- -4.17%
- -28.52%
- 1Y return
- +11.38%
- -5.02%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2023
- News (4w)
- 20
- 3
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest LXEO
- Chief Operating Officer Otero Jose Manuel sold $6,606 worth of shares (1,302 units at $5.07), decreasing direct ownership by 0.99% to 130,088 units (SEC Form 4) (for withholding tax)
- Chief Executive Officer Townsend Richard Nolan sold $16,927 worth of shares (3,342 units at $5.06), decreasing direct ownership by 0.98% to 336,764 units (SEC Form 4) (for withholding tax)
- Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
- SEC Form 4 filed by Director Sepp-Lorenzino Laura
- SEC Form 3 filed by new insider Sepp-Lorenzino Laura
- SEC Form DEFA14A filed by Lexeo Therapeutics Inc.